- Disappointing clinical results for BEN-2293
- Decreased revenues from AstraZeneca collaboration
- Headcount reduction leading to increased staff attrition
BenevolentAI S.A.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, BenevolentAI S.A. disclosed greenhouse gas emissions of 5.9K tCO2e/year. By scope: Scope 1: 282.0 tCO2e/year; Scope 2: 280.8 tCO2e/year (market-based + location-based); Scope 3: 5.3K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
5.9K tCO2e/year
2023
Renewable Energy
27% (London office)
of total energy
Water Usage
92 m3/year (London office only)
2023
Waste
8.1 tons/year (London office), 17.8 tons/year (Cambridge lab waste)
2023
Energy Use
2.2M kWh/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 282.0 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 280.8 tCO2e/year (market-based + location-based) |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 5.3K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 5.9K tCO2e/year |
| 2022 | 7.3K tCO2e/year |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced tCO2e from 7,311 in 2022 to 5,904 in 2023
🎯 Climate & Sustainability Targets
🔜 Short-term
- Deliver BEN-8744 topline results in Q1 2024
- Complete BEN-34712 IND-enabling packages by Q2 2024
- Progress early discovery pipeline assets
- Out-license one pipeline asset
📅 Medium-term
- Sign a new collaboration agreement similar to AstraZeneca or Merck
- Complete further market assessment for Knowledge Exploration Tools by early Q2 2024
🔭 Long-term
- Maintain leadership position in AI-driven drug discovery
🌱 ESG Focus Areas
diversity and inclusionattraction and development of talentsafety and wellbeinginnovationproduct qualitycybersecurityethical conductreducing wasteclimate change